Finance

Lists
SHPMY:OTCMKTS
Shanghai Pharmaceuticals Holdings ADR
$7.24
0.00%
(0.00) 1D
Aug 31, 2:05:20 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SHPMY...
Mkt. cap
64.54B
Avg. vol.
38.00
Volume
0.00
52-wk high
$8.32
52-wk low
$7.04
Beta
0.58
Shares outstanding
183.81M
No. of employees
49K
Mkt. cap
64.54B
Avg. vol.
38.00
Volume
0.00
52-wk high
$8.32
52-wk low
$7.04
Beta
0.58
Shares outstanding
183.81M
No. of employees
49K
News stories
From web sources and news partners
Profile
Shanghai Pharmaceuticals is a private-sector Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets. Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges. As of 2020, the company made its presence to the Global Fortune 500 list with the ranking of 473, overall and 124 among 21 other Chinese companies on the list. Shanghai Pharmaceuticals was founded in 1994 and is headquartered in Shanghai. As an investment holding company, it is actively engaged in research, manufacturing and distribution of pharmaceutical and healthcare products in China, that develops and distributes traditional Chinese and chemical drugs, chemical, biochemical and healthcare goods that are applied in various therapeutic fields, including immunoregulation and anti-cancer, immune system and digestion, cardiovascular and anti-infection, nervous system and mental disorder. Wikipedia
About Shanghai Pharmaceuticals Holdings ADR
CEO-
Employees48.6K
FoundedJan 18, 1994
Headquarters-
SectorHealth care provider
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
73.48B
68.51B
75.26B
72.21B
Cost of goods sold
66.03B
60.55B
67.17B
64.09B
Cost of revenue
66.03B
60.55B
67.17B
64.09B
Research and development expenses
556.53M
824.53M
468.22M
502.64M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.70B
4.97B
4.59B
4.65B
Operating expense
5.58B
5.91B
5.47B
5.55B
Total operating expenses
71.60B
66.47B
72.63B
69.64B
Operating income
1.88B
2.04B
2.63B
2.57B
Other non operating income
-84.84M
-63.65M
-47.88M
-7.43M
EBT including unusual items
1.48B
1.52B
2.42B
3.21B
EBT excluding unusual items
1.61B
1.44B
2.27B
3.03B
Income tax expense
485.91M
534.14M
569.09M
720.64M
Effective tax rate
32.89%
35.10%
23.52%
22.43%
Other operating expenses
129.62M
271.29M
132.16M
186.62M
Net income
688.20M
577.49M
1.42B
2.09B
Net profit margin
0.94%
0.84%
1.88%
2.89%
Earnings per share
-
-
-
-
Interest and investment income
206.57M
-
38.70M
873.52M
Interest expense
-393.02M
-470.36M
-347.64M
-358.39M
Net interest expenses
-186.45M
-470.36M
-308.94M
515.13M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.26B
2.54B
3.12B
3.07B
Gain or loss from assets sale
39.99M
-157.15M
-
-179.70M
AI content may include mistakes. Learn more
Google apps